AFMD Affimed Therapeutics: Multiplikator Forward P/S

Affimed develops innovative cancer treatment methods by activating innate immunity. The expected price-to-sales ratio reflects market expectations, where 3.10 is the current level of the metric. The business is not subject to seasonality or macroeconomic downturns. However, the share price remains sensitive to lymphoma treatment successes and R&D spending rates, despite a stable cash reserve.

Affimed monetizes innovations in innate immune activation to combat oncology, where future revenues depend on the commercialization of killer cell activator drugs. The current value of 3.10 reflects the ratio of the company's market capitalization to expected sales, allowing the future P/S multiple to assess the extent to which investor expectations are inflated relative to actual revenue growth rates.